5Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome and incident diabetes:The Mexico City Diabetes Study, Dia- betes Care,2.005,28:175.7.
7Shyangdan D, Clar C, Ghouri N, et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease : a systematic review [J ]. HeahhTechnol Assess, 2011, 15(38) : 1-110.
8Graif M, Yanuka M, Baraz M,et al. Quantitative estimation of attenuation in ultrasound video images: con'elation with histology in diffuse liver disease [J ]Invest Radiol, 2000,35 (5) : 319- 324.
9郑筱.中药新药临床研究指导原则[M].中国医药科技出版社.2002.
10Farrell GC, Chitmri S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region:executive summary [J]. J Gastroenterol Hepatol, 2007,22 (6) : 775-777.